argenx SE (ARGX.BR) stock analysis

In our weekly check, argenx SE is graded B (A to F). Of 23 checks on debt, profit, cash flow and trend: 19 pass, warnings: 2, red flags: 2.

About argenx SE

argenx SE is a Healthcare company (Biotechnology) based in the Netherlands, listed on BRU as ARGX.BR.

What our checks show for ARGX.BR

Red flags

• The gross margin fell by 5 points, to 89.1%: costs are rising faster than prices.
• Thinly traded (about 88 thousand shares a day): buying and selling can move the price.

Warning signs

• Operating cash flow is only 0.66x net profit: part of the reported profit does not arrive as cash.
• The price swings a lot: 40.2% annual volatility. Expect large ups and downs.

Strengths

• Debt is low: 0.01x equity.
• Operating profit covers interest 243 times over.
• The net margin rose by 110 points over 5 years, to 32.4%.
• Analysts expect earnings per share to grow about 32.5% a year over the next years.
• Analysts expect revenue to grow about 31.8% a year over the next years.
• Analysts expect the net margin to improve by 3.1 points from today's 32.4%.

Similar companies

ONC · RVMD · MRNA · REGN · ALNY · GMAB

Questions

What grade does argenx SE (ARGX.BR) have?

In our weekly check, argenx SE is graded B (A to F). Of 23 checks on debt, profit, cash flow and trend: 19 pass, warnings: 2, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of ARGX.BR stock?

This week's biggest flags for argenx SE: Gross margin falling, Thinly traded, Profits not backed by cash. In total 4 of 23 checks show a warning or a red flag.

What does argenx SE do?

argenx SE is a Healthcare company (Biotechnology) based in the Netherlands, listed on BRU as ARGX.BR.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis